National Director of Gastroenterology (GI) for @VeteransHealth; Professor of GI at @UW; Researcher on #colonoscopy for #ColorectalCancer screening (CONFIRM).
Congratulations @gnioannou on your important paper in
@AnnalsofIM on the value of booster vaccines for #COVID19. So proud of you for the great work you are doing!
https://t.co/M4PO1HEwLF
@dmc200802 @NEJM Cologuard has been compared to FIT and colonoscopy for one time use. No studies of incidence or mortality impact of Cologuard available at this time. Three huge studies comparing cancer mortality with non-invasive FIT vs. colonoscopy are underway in US and Europe.
The NordICC study of invitations for screening colonoscopy vs. no screening in @NEJM has generated a lot of debate about the value of #colonoscopy. I hope this Q&A with CNN sheds some additional light on the topic. Screening saves lives!
#GITwitter
https://t.co/iaUa1UPdTf
@GoBluePoopMD@TODAYshow Question of age to start screening is very complicated. #ColonCancer risk increases with age. Starting earlier than 55 will save more lives but will also require more resources per cancer prevented. Screening resources are very limited in many areas. Start at age 45 in the US.
More discussion about the landmark NordICC screening #colonoscopy study. For those who had colonoscopy, #coloncancer mortality was reduced by 50%! While less than we hoped, it is still impressive. Don't cancel your colonoscopy! #GITwitter
https://t.co/iOilDQ2iES via @TODAYshow
@GoBluePoopMD@TODAYshow Early in the study, #colonoscopy finds asymptomatic cancers, looking like scope causes cancer. But removing polyps prevents cancers. Control group cancers won’t be found until symptoms develop. So scope benefits begin to show around 5-10 yrs & may continue to increase with time.
@RashidLui@NEJM The risk of #coloncancer varies by country and ethnicity. Obesity, tobacco, & alcohol use are some of the known risk factors for colon cancer and polyps. These factors can impact study results. Note that Europe has higher colon cancer rates than N America per GLOBOCAN 2020.
@AnnalsofIM study pooled 4 huge studies of sigmoidoscopy (sig). #ColonCancer incidence reduced by 21% and deaths reduced by 20%. All-cause deaths reduced by 2%. #colonoscopy examines the whole colon (sig examines only ~1/2), so benefits should be greater!
https://t.co/dsl7UMhmu0
Though the NordICC study leaves many questions unanswered, it does confirm that #colonoscopy reduces #colorectalcancer incidence. For those who were invited and had a colonoscopy, it reduced colon cancer-related deaths by 50%! Screening adherence is the key to cancer prevention.
@cchildersmd@NEJM There is also reason to believe colonoscopy can do even better! It appears higher risk individuals may have been more likely to agree to colonoscopy in NordICC. With high quality colonoscopy, I do believe we can reduce mortality by >50%.
Surprised by landmark @NEJM study results as #colonoscopy only reduced #coloncancer incidence by 18% with no significant mortality reduction at 10 yrs. But only 42% had procedure. For those who had colonoscopy, mortality reduced by 50%! #GITwitter
https://t.co/FI1QclO7SE
@bens908 @NEJM Death from any cause was 11.03% with colo invitation vs. 11.04% with usual care. But the study was not designed to compare all-cause mortality, only CRC-related deaths. CRC death was 0.28% vs. 0.31% (risk ratio 0.9) in ITT analysis. Per protocol (0.15% vs. 0.30%, risk ratio 0.5).
New editorial by Jason A. Dominitz, M.D., M.H.S., and Douglas J. Robertson, M.D., M.P.H.: "Understanding the Results of a Randomized Trial of Screening Colonoscopy" https://t.co/0hYZe7T7RO